Securities Fraud Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA)

A securities fraud class action lawsuit has been initiated against Iovance Biotherapeutics, Inc. (IOVA), reminding investors of the upcoming deadline of July 14, 2025. The lawsuit alleges that the company may have issued misleading or false statements to investors, leading to financial losses for shareholders.

Investors who purchased shares of Iovance Biotherapeutics between May 9, 2019, and May 27, 2021, may be eligible to join the class action lawsuit. The company is facing allegations that it made misleading statements regarding the efficacy of its tumor-infiltrating lymphocyte (“TIL”) therapy in treating patients with advanced cervical cancer. These alleged misrepresentations artificially inflated the company’s stock price, leading to financial losses for investors when the truth was revealed.

According to the lawsuit, Iovance Biotherapeutics failed to disclose crucial information about its TIL therapy’s efficacy and tumor responses, despite claims made by company executives. This alleged omission misled investors about the potential success of the treatment and caused them to suffer financial harm when the stock price plummeted after the truth came to light.

Investors who suffered financial losses as a result of investing in Iovance Biotherapeutics during the specified time frame are encouraged to join the class action lawsuit. By participating in the legal action, investors may be able to recover some of their losses incurred due to the alleged securities fraud committed by the company.

If you purchased shares of Iovance Biotherapeutics between May 9, 2019, and May 27, 2021, and experienced financial losses, you may be eligible to participate in the class action lawsuit. The lawsuit is seeking to hold the company accountable for its alleged securities fraud and to provide restitution to investors who were harmed as a result.

Investors are reminded of the upcoming deadline of July 14, 2025, to join the class action lawsuit against Iovance Biotherapeutics. By taking legal action against the company, investors may be able to recoup some of their losses and hold the company accountable for its alleged misconduct. If you believe you have a valid claim against Iovance Biotherapeutics, it is crucial to act promptly and join the class action lawsuit before the deadline passes.